The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the paroxysmal nocturnal hemoglobinuria (pnh) industry?
The rising number of blood disorders and bone marrow-related disorders is expected to propel the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market going forward. Blood disorders are medical conditions that affect the composition, function and production of blood and its components. Bone marrow-related disorders occur when either insufficient red, white, or platelet production occurs in the bone marrow or when the blood cells that are generated are damaged or defective. PNH is closely related to blood disorders and bone marrow-related disorders due to its impact on blood cell production, immune system function and the bone marrow microenvironment. It is a rare blood disorder that is related to bone marrow failure diseases and occurs when a genetic flaw affects how red blood cells and platelets work. For instance, in August 2022, according to Cancer Australia, an Australia-based government agency in 2022, an estimated 5,202 new cases of leukemia will be diagnosed in Australia, with 3,198 cases among males and 2,004 among females. A person has a 1 in 58 (or 1.7%) chance of being diagnosed with leukemia by age 85. This risk is higher for males, at 1 in 47 (2.1%), compared to females, at 1 in 77 (1.3%). Therefore, the rising number of blood disorders and bone marrow-related disorders is driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.
Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Driver: Rising Demand For Blood Transfusions Drives The Growth Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market
The rising demand for blood transfusions is expected to drive the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market. A blood transfusion is a medical procedure involving the transfer of blood or blood products from a donor to a recipient. Blood transfusions can be beneficial for individuals with paroxysmal nocturnal hemoglobinuria (PNH) by providing temporary relief from the symptoms and complications associated with this condition. For instance, in June 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, in high-income nations, which comprise only 16% of the world’s population, the proportion of blood donations was remarkably significant, accounting for 40% of the total 118.5 million blood donations made worldwide. Additionally, in December 2022, according to the Government of Canada, a Canada-based intergovernmental organization, the UK witnessed an increase in blood donations, with 1.7 million donations made across the country in 2021. Therefore, the rising demand for blood transfusions drives the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp
What is the estimated market size of the paroxysmal nocturnal hemoglobinuria (pnh) sector by 2029, based on current forecasts?
The paroxysmal nocturnal hemoglobinuria (PNH) market size has grown rapidly in recent years. It will grow from $4.24 billion in 2024 to $4.68 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growing demand for paroxysmal nocturnal hemoglobinuria treatment, rising disposable incomes, government initiatives, rising healthcare expenditure.
The paroxysmal nocturnal hemoglobinuria (PNH) market size is expected to see strong growth in the next few years. It will grow to $6.69 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12936&type=smp
#Who are the top players in the paroxysmal nocturnal hemoglobinuria (pnh) market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.
#What are the major trends in the paroxysmal nocturnal hemoglobinuria (pnh) market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are focusing on developing new and innovative drugs and therapies, such as injectable C5 inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), to sustain their position in the market. An injectable C5 inhibitor is a monoclonal antibody that blocks the complement component C5, reducing inflammation and tissue damage in autoimmune diseases and conditions like paroxysmal nocturnal hemoglobinuria (PNH). For instance, in February 2024, Chugai Pharmaceutical Co., a Japan-based pharmaceutical company, received priority review approval from China’s National Medical Products Administration (NMPA) for treating paroxysmal nocturnal hemoglobinuria (PNH). This marks China as the first country to approve PIASKY, ahead of other major markets, allowing it to enter National Reimbursement Drug List (NRDL) negotiations within the same year. PNH, classified as a rare disease, affects an estimated 12,740 individuals in China, presenting significant market potential.
Which geography holds the highest paroxysmal nocturnal hemoglobinuria (pnh) market share?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
How do different segments contribute to the overall expansion of the paroxysmal nocturnal hemoglobinuria (pnh) market?
The paroxysmal nocturnal hemoglobinuria (PNH) market covered in this report is segmented –
1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types
2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types
3) By End Use: Hospitals, Clinics, Other End Users
Subsegments:
1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications
2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation
3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion
4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil
5) By Other Treatment Types: Supportive Therapies, Management Of Complications
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12936
What defines the structure and scope of the paroxysmal nocturnal hemoglobinuria (pnh) market?
Paroxysmal nocturnal hemoglobinuria (PNH) refers to a rare and acquired hematological disorder characterized by the abnormal breakdown of red blood cells (hemolysis) due to a deficiency of certain proteins on the surface of blood cells. It is a debilitating disorder that leads to premature death and impaired production of blood cells. PNH includes a wide range of symptoms, such as fatigue, shortness of breath, abdominal pain and thrombosis (blood clot formation).
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
